Dupixent (dupilumab) is a biologic injection made by Regeneron and Sanofi. As of 2026 it has FDA approval for nine indications: moderate-to-severe atopic dermatitis (ages 6 months and older), eosinophilic or steroid-dependent asthma (adults and pediatric patients), chronic rhinosinusitis with nasal polyps (ages 12 and older), eosinophilic esophagitis (ages 1 and older, at least 15 kg), prurigo nodularis (adults), COPD with eosinophilic phenotype (adults), chronic spontaneous urticaria (ages 2 and older), bullous pemphigoid (adults), and allergic fungal rhinosinusitis (ages 6 and older). It works by blocking the IL-4 and IL-13 receptor alpha subunit, which are the signaling pathways that drive type 2 inflammatory responses across all these conditions.
As of mid-2026, dupilumab has no FDA-approved biosimilar in the United States. Patent protections extend through the mid-2030s. This means no generic or lower-cost equivalent is available at any US pharmacy. The drug occupies the highest-cost specialty tier on most commercial and Medicare Part D formularies. Manufacturer savings programs, specifically the DUPIXENT MyWay copay card and patient assistance program, are the primary tools for reducing out-of-pocket cost for eligible patients.
Prior authorization is required by virtually all commercial insurers and Medicare Part D plans. For atopic dermatitis, most plans require documented failure of at least two topical therapies before approving Dupixent. For asthma, plans typically require documented eosinophilic phenotype (blood eosinophils of 150 cells per microliter or more) or oral steroid dependence, plus maximized inhaled controller therapy. Initial denials are common, but appeals and peer-to-peer reviews succeed at high rates when documentation is complete. Step-therapy override rights under state law and federal Medicare regulations provide a mechanism to bypass automatic denials when alternatives are medically contraindicated. Patients managing multiple specialty drugs should also review how the annual out-of-pocket maximum interacts with their deductible under their plan. Related biologics like Humira operate under similar prior authorization requirements.
What Dupixent Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same dupixent can cost many times more at a hospital than at your local pharmacy:
2026 Dupixent Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy (cash, no insurance or discount program) | $3,993 - $5,449/month | Manufacturer list price $4,193 per carton (2 syringes) as of January 2, 2026; monthly cost depends on dose schedule (200 mg or 300 mg every 2 weeks) |
| Commercially insured with DUPIXENT MyWay copay card | $0/fill (up to $13,000/year covered by card) | Must have commercial insurance; copay card not available to Medicare or Medicaid patients under federal anti-kickback law |
| Medicare Part D (2026) | $2,100 annual OOP cap (then $0 for rest of year) | Dupixent covered by approximately 99% of Part D plans; copay card not applicable to Medicare patients; Extra Help enrollees pay reduced copay |
| DUPIXENT MyWay PAP (uninsured, income-eligible) | $0 (free drug for qualifying patients) | Income at or below approximately 400% FPL ($63,840 for household of 1 in 2026); uninsured or underinsured; evaluated case by case |
| Inpatient or outpatient facility charge (in-office administration) | $5,000 - $8,500/administration | When administered in-office or at a hospital outpatient department; billed as J3590 (unclassified biologic); most patients self-inject at home under Part D |
| Medicaid | $1 - $4/prescription | Coverage and prior authorization requirements vary by state; copay card not applicable to Medicaid patients |
List price sourced from Regeneron/Sanofi January 2, 2026 disclosure. Retail range reflects GoodRx and specialty pharmacy data. Facility charge range is an estimate based on CMS Hospital Price Transparency files for specialty biologic administration. DUPIXENT MyWay PAP income threshold based on Sanofi Patient Connection program terms as reported by RxAssist and NeedyMeds.
Source: Regeneron/Sanofi, GoodRx 2026, CMS Hospital Price Transparency, NeedyMeds.org
Why Hospitals Charge So Much
When a physician administers Dupixent in-office or a hospital outpatient department provides it during a visit, the facility bills the drug separately using HCPCS code J3590 (unclassified biologic). Because Dupixent lacks a permanent HCPCS J-code, providers must include the drug's National Drug Code (NDC) number, dose, and a narrative in the claim. Facilities add a markup on top of their acquisition cost. Hospital outpatient facilities may charge $5,000 to $8,500 per administration even though wholesale acquisition cost for a two-syringe carton runs $2,000 to $4,000. The gap reflects facility overhead, nursing administration, and standard markups that are built into chargemaster rates.
For most patients, Dupixent is self-administered at home via prefilled syringe. This makes it a Part D drug dispensed through a specialty pharmacy rather than a Part B drug billed by a facility. In the home self-injection setting, the hospital chargemaster markup is bypassed entirely. What you see is the specialty pharmacy's price plus your cost-sharing under Part D or the commercial formulary. The $2,100 annual Part D out-of-pocket cap and the DUPIXENT MyWay copay card are both relevant only in this pharmacy channel, not for in-office administration claims. Medicare beneficiaries who qualify for Extra Help can reduce their specialty drug cost-sharing significantly.
Dupixent is not subject to Medicare Part B ASP pricing because it is not infused intravenously in a clinical setting. It is self-injected subcutaneously and distributed through specialty pharmacy channels. CMS does not publish a quarterly ASP rate for Dupixent the way it does for IV-infused biologics like rituximab or pembrolizumab. If a provider bills Dupixent under Part B using J3590 in an unusual clinical situation, the reimbursement is based on the submitted invoice price rather than a published ASP file, and the provider must include supporting documentation.
HCPCS J-Codes: What Appears on Your Bill
Dupixent does not have a permanent HCPCS Level II J-code as of 2026. When administered in a physician office or hospital outpatient setting, it is billed under an unclassified biologic code. Understanding this code helps you verify your bill and spot billing errors:
HCPCS J-codes for Dupixent| Code | Description | What to look for |
|---|
| J3590 | Unclassified biologics (used for dupilumab/Dupixent when administered in-office or outpatient facility setting) | Must be accompanied by the drug's NDC number, the dose administered, and a narrative identifying dupilumab; the code should not appear for self-administered home doses dispensed through specialty pharmacy |
J3590 is a public-domain HCPCS Level II code maintained by CMS. Dupixent has no permanent J-code (such as a J0XXX assignment) as of 2026. When Dupixent is dispensed through specialty pharmacy for home self-injection, no J-code appears on the pharmacy Explanation of Benefits; the drug is covered under Part D, not Part B. If you see J3590 on a facility bill for a dose you self-administered at home, that is a potential billing error to dispute.
Source: CMS HCPCS Level II Coding, CMS.gov
Patient Assistance Programs
Regeneron and Sanofi operate the DUPIXENT MyWay program, which includes both a commercial copay card and a patient assistance program for uninsured or underinsured patients. These are two separate pathways. IMPORTANT: Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits manufacturer copay cards from being used by patients covered by Medicare, Medicaid, TRICARE, or VA. Medicare Part D patients use the $2,100 annual OOP cap and should apply for Part D Extra Help if cost sharing is unaffordable. The patient assistance free-drug program may be available to Medicare patients in specific circumstances after other options are exhausted:
Patient assistance programs for Dupixent| Manufacturer program | Cost / Benefit | How to apply |
|---|
| DUPIXENT MyWay Copay Card (commercially insured patients only) | $0/fill for most commercially insured patients; up to $13,000 per calendar year covered by the card; not available to Medicare or Medicaid patients | dupixent.com/support-savings/cost-insurance |
| DUPIXENT MyWay Patient Assistance Program (uninsured or underinsured) | Free Dupixent for eligible patients; income threshold approximately 400% FPL ($63,840 for household of 1 in 2026); evaluated case by case; must be uninsured or underinsured for Dupixent | dupixent.com/support-savings/cost-insurance |
| Sanofi Patient Connection (alternative PAP channel) | Alternative application channel through the broader Sanofi patient assistance network; income-based eligibility evaluated case by case for patients meeting financial hardship criteria | sanofipatientconnection.com |
| HealthWell Foundation (Medicare patients needing grant assistance) | Independent charitable foundation grants to cover cost sharing for Medicare patients with eczema or asthma indications; grant availability varies by funding period | healthwellfoundation.org |
The DUPIXENT MyWay copay card is not available to patients whose primary insurance is Medicare or Medicaid. Medicare patients may apply for Part D Extra Help (Low Income Subsidy) through Social Security at 1-800-772-1213 or ssa.gov. Extra Help reduces cost sharing significantly for Medicare beneficiaries with income at or below 150% FPL ($23,940 for a single person in 2026). Independent foundations such as HealthWell, Patient Advocate Foundation, and National Organization for Rare Disorders (NORD) may offer grants to cover Medicare cost sharing for Dupixent-treated conditions. Call DUPIXENT MyWay at 1-844-387-4936 (option 1) Monday through Friday 8 AM to 9 PM EST to confirm current program details and eligibility.
Source: dupixent.com, sanofipatientconnection.com, NeedyMeds.org, healthwellfoundation.org
Medicare Part D
Dupixent is covered by approximately 99% of Medicare Part D prescription drug plans as a specialty tier drug. In 2026, the Part D annual out-of-pocket cap is $2,100. Once you spend $2,100 out of pocket in a calendar year across all covered Part D drugs, your cost drops to $0 for the rest of the year. For a drug costing $4,000 to $5,000 per month at list price, most Medicare patients will hit the $2,100 cap after the first month or two of therapy. All out-of-pocket spending at any Part D network specialty pharmacy counts toward the cap.
The manufacturer copay assistance card (DUPIXENT MyWay) does not work with Medicare Part D. Federal anti-kickback rules prohibit manufacturers from offsetting cost sharing for government-insured patients. Medicare patients who cannot afford the initial out-of-pocket spending before reaching the $2,100 cap can apply for Part D Extra Help (Low Income Subsidy) through the Social Security Administration at 1-800-772-1213. Extra Help is available to Medicare beneficiaries with income at or below 150% FPL (approximately $23,940 for a single person in 2026) and significantly reduces cost sharing. Independent charitable foundations such as HealthWell Foundation and Patient Advocate Foundation may also offer grants to cover cost sharing for Medicare patients with eczema or asthma.
Dupixent is not one of the drugs selected for IRA Medicare drug price negotiation in the first or second negotiation rounds. The IRA drug negotiation program selects high-spend drugs with expired small-molecule exclusivity; Dupixent is a biologic with active patent protection through the mid-2030s. As a result, there is no federally negotiated Maximum Fair Price for Dupixent. Medicare patients pay under standard Part D coverage rules including the $2,100 annual cap.
Common Dupixent Billing Errors
Dupixent billing is prone to specific errors because it lacks a permanent HCPCS J-code and operates differently under Part B versus Part D depending on the administration setting. Watch for these on your Explanation of Benefits or facility bill:
- Facility billing J3590 (Part B in-office administration) for a dose the patient actually self-administered at home under Part D; this results in a duplicate charge. If you see J3590 on a claim for a date when you were not at a provider's office, that is a billing error.
- Wrong dose billed: Dupixent comes in 200 mg and 300 mg prefilled syringes for different indications and dose schedules. Billing for the 300 mg dose when the 200 mg dose was dispensed inflates the charge by approximately 50 percent. Check the NDC number on your bill against your prescription.
- Prior authorization not updated after a dose change or new FDA indication; this causes claim denial that the patient is incorrectly told to pay out of pocket. A PA obtained for 200 mg every 2 weeks does not automatically cover 300 mg every 2 weeks for a different indication.
- DUPIXENT MyWay copay card benefit not applied at specialty pharmacy, resulting in the patient being charged the full cost-share or specialty tier copay. If the copay card is active and you were charged more than $0, contact the pharmacy and DUPIXENT MyWay at 1-844-387-4936 immediately.
- Administration fee billed twice for a bilateral injection (two syringes administered in one visit); only one J3590 code should appear with a quantity of 2 and the correct NDC and dose narrative.
- Part D plan charging coinsurance based on the undiscounted list price instead of the negotiated specialty pharmacy rate, resulting in overpayment before the $2,100 annual OOP cap is correctly applied. If your EOB shows a cost-share figure that seems higher than expected relative to the $2,100 annual cap, request a detailed cost-share calculation from your plan.
Frequently Asked Questions
How much does Dupixent cost per month without insurance in 2026?
Dupixent's list price is $4,193 per carton (2 prefilled syringes) as of January 2, 2026, per Regeneron and Sanofi. At specialty pharmacies paying cash without insurance, prices range from $3,993 to $5,449 per month depending on the dose and pharmacy. Some dose schedules require two cartons per month (for example, 300 mg every two weeks for certain indications), which can push the monthly cost above $8,000. No biosimilar is available in the US as of mid-2026.
Does Medicare cover Dupixent in 2026?
Yes. Approximately 99% of Medicare Part D prescription drug plans cover Dupixent as a specialty tier drug. It is covered under Part D (not Part B) because most patients self-inject at home rather than receiving infusions in a clinical setting. Under 2026 Part D rules, patients are protected by a $2,100 annual out-of-pocket cap. After reaching the cap in a calendar year, the patient pays $0 for Dupixent for the rest of the year. Prior authorization is required. Dupixent was not selected for IRA Medicare drug price negotiation, so there is no federally negotiated Maximum Fair Price.
What is the DUPIXENT MyWay copay card and who qualifies?
The DUPIXENT MyWay copay card is a manufacturer savings program run by Regeneron and Sanofi for patients with commercial insurance (employer plans, marketplace plans, and individual private plans). Eligible commercially insured patients pay as little as $0 per fill, with the card covering up to $13,000 per calendar year. Patients on Medicare or Medicaid are not eligible for the copay card under federal anti-kickback statute. To enroll, call 1-844-387-4936 or visit dupixent.com.
How do I qualify for free Dupixent through the patient assistance program?
The DUPIXENT MyWay Patient Assistance Program provides free Dupixent to uninsured or underinsured patients who meet income and residency requirements. Income threshold is approximately 400% of the Federal Poverty Level, which is $63,840 for a single-person household in 2026. Eligibility is evaluated case by case. You must be a US resident and have a valid prescription. Medicare Part D patients typically must first apply for Extra Help (Low Income Subsidy) at 1-800-772-1213 before the PAP will review the application. Apply by calling 1-844-387-4936 (option 1) or visiting dupixent.com.
Is there a generic or biosimilar for Dupixent in 2026?
No. Dupilumab (Dupixent) is a biologic monoclonal antibody. No FDA-approved biosimilar exists as of mid-2026. Patent protections for the dupilumab molecule and the dual IL-4/IL-13 receptor inhibition mechanism extend through the mid-2030s. Because dupilumab is a biologic, any future lower-cost version would be approved as a biosimilar (not a generic) through the FDA's BPCIA pathway. Patients should not expect biosimilar competition to reduce prices before approximately 2035.
What HCPCS code is used for Dupixent billing?
Dupixent does not have a permanent HCPCS Level II J-code as of 2026. When administered in a physician office or hospital outpatient setting, it is billed under J3590 (unclassified biologics), along with the drug's NDC number, dose, and a narrative. For most patients who self-inject at home, no J-code appears on their pharmacy bill because the drug is dispensed under Part D. If you see a J3590 charge on a facility bill for a date when you were not physically in a provider's office, that is a potential billing error to dispute.
Why does my insurance require prior authorization for Dupixent?
Prior authorization is required because Dupixent costs approximately $48,000 to $65,000 per year at list price. Insurers require documented evidence that the patient has tried lower-cost first-line treatments and not responded adequately. For atopic dermatitis (eczema), this typically means documented failure of at least two topical therapies such as corticosteroids and calcineurin inhibitors. For asthma, it means blood eosinophil counts above 150 cells per microliter or documented oral steroid dependence. Initial denials are common but can be appealed. A peer-to-peer review between your prescriber and the plan's medical director succeeds at high rates when documentation is thorough.
What conditions is Dupixent FDA-approved for in 2026?
As of 2026, Dupixent (dupilumab) is FDA-approved for nine indications: moderate-to-severe atopic dermatitis (ages 6 months and older), eosinophilic or steroid-dependent asthma, chronic rhinosinusitis with nasal polyps (ages 12 and older), eosinophilic esophagitis (ages 1 and older), prurigo nodularis (adults), COPD with eosinophilic phenotype (adults), chronic spontaneous urticaria (ages 2 and older), bullous pemphigoid (adults), and allergic fungal rhinosinusitis (ages 6 and older). Each indication may have different prior authorization criteria and dose requirements.
